β-L-idopyranuronic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: β-L-idopyranuronic acid
• 英文别名: β-L-IdoA；(2R,3S,4S,5R,6S)-3,4,5,6-Tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid；(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
• 化学式: C₆H₁₀O₇
• 分子量: 194.141
• InChiKey: AEMOLEFTQBMNLQ-URDJKYRMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  D-glucurono-3,6-lactone acetonide 在 吡啶 、 水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 α-L-idopyranuronic acid 、 β-L-idopyranuronic acid
  参考文献：
  名称：

  Improved one-pot multienzyme (OPME) systems for synthesizing UDP-uronic acids and glucuronides

  摘要：

  高效的一锅多酶（OPME）系统已经建立起来，用于从简单单糖合成UDP-GlcA、UDP-GalA和葡萄糖醛酸酯。

  DOI：

  10.1039/c4cc10306h

文献信息

• CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US20150238597A1

  公开（公告）日：2015-08-27

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

  本发明涉及合成和生物评价一种新型基于碳水化合物的疫苗的领域。这种新疫苗由多模块结构组成，可以将疫苗应用于各种病原体。该方法允许制备针对所有表达免疫原碳水化合物抗原的病原体的疫苗。由于不需要将抗原碳水化合物与蛋白质结合，所以结合疫苗尤其耐热稳定。无需冷藏，这是基于蛋白质的疫苗的一个主要缺点。
• Carbohydrate-glycolipid conjugate vaccines
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US10588962B2

  公开（公告）日：2020-03-17

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

  本发明涉及一类基于碳水化合物的新型疫苗的合成和生物评估领域。这种新型疫苗由多模块结构组成，可将疫苗应用于各种病原体。这种方法可以制备出针对所有表达免疫原性碳水化合物抗原的病原体的疫苗。由于不需要将抗原碳水化合物与蛋白质共轭，共轭疫苗的热稳定性特别好。无需冷藏，这是基于蛋白质的疫苗的一个主要缺点。
• EP1353556A4
  申请人：——

  公开号：EP1353556A4

  公开（公告）日：2009-09-09
• SOLID- AND SOLUTION -PHASE SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS
  申请人：MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：EP1353556A2

  公开（公告）日：2003-10-22
• [EN] SOLID- AND SOLUTION -PHASE SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS<br/>[FR] SYNTHESE DE L'HEPARINE ET D'AUTRES GLYCOSAMINOGLYCANES EN PHASE SOLIDE ET EN PHASE SOLUTION
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2002058633A2

  公开（公告）日：2002-08-01

  Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specifi sequences involved in receptor binding holds great promise for the develpment of molecular tools which will allow modulation of processes underlying viral entry, angiog enesis, kidney diseases and diseases of the control nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.